Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...

ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...

GeoVax Labs Inc. reported its financial results for the first quarter of 2025, showing revenues of 1.6 million dollars, primarily derived from a BARDA contract. The company experienced a net loss ...

Detailed price information for Geovax Labs (GOVX-Q) from The Globe and Mail including charting and trades.

--GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a ...

David Dodd, GeoVax President and CEO, commented, “This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 120 ...

GeoVax has other ongoing Phase 2 trials assessing GEO-CM04S1 as a primary vaccine for immunocompromised patients and as a durable booster for individuals previously vaccinated with mRNA vaccines.

If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at [email protected]. GeoVax Labs, Inc. is a ...

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers.